Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 13/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20520537 | 0.84 | SMN1; SMN2 (0.37) | GSK3BALDH1A1NPC1MAPTRAB9A | |
| SCHEMBL21853882 | 0.82 | ALDH1A1 (0.38) | GSK3BALDH1A1NPC1MAPTRAB9A | |
| SCHEMBL21862393 | 0.82 | SMN1; SMN2 (0.36) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL293931 | 0.77 | — | — | |
| SCHEMBL3052942 | 0.77 | — | — | |
| SCHEMBL23959903 | 0.77 | FAAH (0.40) | ALDH1A1NPC1SMN1; SMN2LMNA | |
| SCHEMBL20520527 | 0.75 | ALDH1A1 (0.41) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL21841051 | 0.75 | FAAH (0.42) | NPC1 | |
| SCHEMBL4966007 | 0.75 | — | — | |
| SCHEMBL2057950 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565493-B2 | Method for preparing 2-[2-(2-chlorothiazol-5-yl)-2-oxo-ethyl]sulfanyl-6-hydroxy-3-methyl-5-phenyl-pyrimidin-4-one | BASF SE (DE) | 2026-03-03 | — | — | US | claimed |
| US-12516030-B2 | Preparation of 2-chloro-1-(2-chlorothiazol-5-yl)ethanone | BASF SE (DE) | 2026-01-06 | — | — | US | claimed |
| US-12365657-B2 | Preparation of 2-chloro-1-(2-chlorothiazol-5-yl)ethanone | BASF SE (DE) | 2025-07-22 | — | — | US | claimed |
| CN-114555568-B | Preparation of 2-chloro-1- (2-chlorothiazol-5-yl) ethanone | 巴斯夫欧洲公司 | 2025-01-24 | — | — | CN | claimed |
| US-20240101547-A1 | METHOD FOR PREPARING 2-[2-(2-CHLOROTHIAZOL-5-YL)-2-OXO-ETHYL]SULFANYL-6-HYDROXY-3-METHYL-5-PHENYL-PYRIMIDIN-4-ONE | BASF SE (DE) | 2024-03-28 | — | — | US | claimed |
| US-20240051929-A1 | PREPARATION OF 2-CHLORO-1-(2-CHLOROTHIAZOL-5-YL)ETHANONE | BASF SE (DE) | 2024-02-15 | — | — | US | claimed |
| EP-4281441-A1 | METHOD FOR PREPARING 2-[2-(2-CHLOROTHIAZOL-5-YL)-2-OXO-ETHYL]SULFANYL-6-HYDROXY-3-METHYL-5-PHENYL-PYRIMIDIN-4-ONE | BASF SE (DE) | 2023-11-29 | — | — | EP | claimed |
| EP-4038056-B1 | PREPARATION OF 2-CHLORO-1-(2-CHLOROTHIAZOL-5-YL)ETHANONE | BASF SE (DE) | 2023-11-08 | — | — | EP | claimed |
| US-20230322693-A1 | PREPARATION OF 2-CHLORO-1-(2-CHLOROTHIAZOL-5-YL)ETHANONE | BASF SE (DE) | 2023-10-12 | — | — | US | claimed |
| CN-116783169-A | Process for preparing 2- [2- (2-chlorothiazol-5-yl) -2-oxoethyl ] sulfanyl-6-hydroxy-3-methyl-5-phenylpyrimidin-4-one | 巴斯夫欧洲公司 | 2023-09-19 | — | — | CN | claimed |
| EP-4222145-A1 | PREPARATION OF 2-CHLORO-1-(2-CHLOROTHIAZOL-5-YL)ETHANONE | BASF SE (DE) | 2023-08-09 | — | — | EP | claimed |
| CN-116018339-A | Preparation of 2-chloro-1- (2-chlorothiazol-5-yl) ethanone | 巴斯夫欧洲公司 | 2023-04-25 | — | — | CN | claimed |
| CN-114555568-A | Preparation of 2-chloro-1- (2-chlorothiazol-5-yl) ethanone | 巴斯夫欧洲公司 | 2022-05-27 | — | — | CN | claimed |
| WO-2021063880-A1 | PREPARATION OF 2-CHLORO-1-(2-CHLOROTHIAZOL-5-YL)ETHANONE | BASF SE (DE) | 2021-04-08 | — | — | WO | claimed |
| US-12565493-B2 | Method for preparing 2-[2-(2-chlorothiazol-5-yl)-2-oxo-ethyl]sulfanyl-6-hydroxy-3-methyl-5-phenyl-pyrimidin-4-one | BASF SE (DE) | 2026-03-03 | — | — | US | disclosed |
| US-12559507-B2 | Method for preparing an enantiomerically enriched form of 3-(2-chlorothiazol-5-yl)-8-methyl-7-oxo-6-phenyl-2,3-dihydrothiazolo[3,2-ajpyrimidin-4-ium-5-olate | BASF SE (DE) | 2026-02-24 | — | — | US | disclosed |
| EP-4281461-B1 | METHOD FOR PREPARING AN ENANTIOMERICALLY ENRICHED FORM OF 3-(2-CHLOROTHIAZOL-5-YL)-8-METHYL-7-OXO-6-PHENYL-2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM-5-OLATE | BASF SE (DE) | 2026-01-21 | — | — | EP | disclosed |
| WO-2018202654-A1 | PROCESS FOR PREPARING CHIRAL 2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM COMPOUNDS | BASF SE (DE) | 2018-11-08 | — | — | WO | disclosed |
| WO-2018197541-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM COMPOUNDS | BASF SE (DE) | 2018-11-01 | — | — | WO | disclosed |
| WO-2018177970-A1 | PROCESS FOR PREPARING CHIRAL 2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM COMPOUNDS | BASF SE (DE) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565493-B2 | Method for preparing 2-[2-(2-chlorothiazol-5-yl)-2-oxo-ethyl]sulfanyl-6-hydroxy-3-methyl-5-phenyl-pyrimidin-4-one | TPMT, UMPS, TST | GSK3B 4019/4885ALDH1A1 213/4885NPC1 2596/4885 |
| US-12559507-B2 | Method for preparing an enantiomerically enriched form of 3-(2-chlorothiazol-5-yl)-8-methyl-7-oxo-6-phenyl-2,3-dihydrothiazolo[3,2-ajpyrimidin-4-ium-5-olate | HAO2, TPMT, HPRT1 | GSK3B 1733/4885ALDH1A1 223/4885NPC1 3391/4885 |
| US-20230322693-A1 | PREPARATION OF 2-CHLORO-1-(2-CHLOROTHIAZOL-5-YL)ETHANONE | CYP2J2, CLK2, CLK1 | GSK3B 4124/4885ALDH1A1 316/4885NPC1 1515/4885 |
| US-20240101547-A1 | METHOD FOR PREPARING 2-[2-(2-CHLOROTHIAZOL-5-YL)-2-OXO-ETHYL]SULFANYL-6-HYDROXY-3-METHYL-5-PHENYL-PYRIMIDIN-4-ONE | TPMT, TH, UMPS | GSK3B 3347/4885ALDH1A1 405/4885NPC1 3876/4885 |
| US-20240051929-A1 | PREPARATION OF 2-CHLORO-1-(2-CHLOROTHIAZOL-5-YL)ETHANONE | CYP2J2, CLK2, CLK1 | GSK3B 4124/4885ALDH1A1 316/4885NPC1 1515/4885 |
| US-12365657-B2 | Preparation of 2-chloro-1-(2-chlorothiazol-5-yl)ethanone | CYP2J2, CLK2, CLK1 | GSK3B 4124/4885ALDH1A1 316/4885NPC1 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.